Assessing Response to Treatment in Non-Small-Cell Lung Cancer: Role of Tumor Volume Evaluated By Computed Tomography

Knollmann, Friedrich D.; Kumthekar, Rohan; Fetzer, David; Socinski, Mark A.
March 2014
Clinical Lung Cancer;Mar2014, Vol. 15 Issue 2, p103
Academic Journal
No abstract available.


Related Articles

  • Standard uptake value and metabolic tumor volume of F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer. Wei Huang; Tao Zhou; Li Ma; Hongfu Sun; Heyi Gong; Juan Wang; Jinming Yu; Baosheng Li // European Journal of Nuclear Medicine & Molecular Imaging;Sep2011, Vol. 38 Issue 9, p1628 

    Purpose: The aim of this study is to investigate the role of standard uptake values (SUVs) and metabolic tumor volume (MTV) in [F]fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) to predict the short-term outcome of chemoradiotherapy (CRT) in patients with...

  • PET/CT in the Staging of the Non-Small-Cell Lung Cancer. Fangfang Chao; Hong Zhang // Journal of Biomedicine & Biotechnology;2012, Vol. 2012, p1 

    Lung cancer is a common disease and the leading cause of cancer-related death in many countries. Precise staging of patients with non-small-cell lung cancer plays an important role in determining treatment strategy and prognosis. Positron emission tomography/computed tomography (PET/CT),...

  • Integrin-Targeted Hybrid Fluorescence Molecular Tomography/X-ray Computed Tomography for Imaging Tumor Progression and Early Response in Non-Small Cell Lung Cancer. Xiaopeng Ma; Van, Valerie Phi; Kimm, Melanie A.; Prakash, Jaya; Kessler, Horst; Kosanke, Katja; Feuchtinger, Annette; Aichler, Michaela; Gupta, Aayush; Rummeny, Ernst J.; Eisenblätter, Michel; Siveke, Jens; Walch, Axel K.; Braren, Rickmer; Ntziachristos, Vasilis; Wildgruber, Moritz // Neoplasia;Jan2017, Vol. 19 Issue 1, p8 

    Integrins play an important role in tumor progression, invasion and metastasis. Therefore we aimed to evaluate a preclinical imaging approach applying ανβ3 integrin targeted hybrid Fluorescence Molecular Tomography/X-ray Computed Tomography (FMT-XCT) for monitoring tumor progression as...

  • Early Proof Possible of Successful Cancer Treatment.  // Pulmonary Reviews;Aug2007, Vol. 12 Issue 8, p18 

    The article reports on the use of positron emission tomography (PET) to assess the success of a cancer radiation treatment. In a study conducted among 15 people with early stage non-small cell lung cancer, fluorodeoxyglucose (FDG) PET was administered before, during and after therapy. A...

  • Imaging.  // Current Medical Literature: Lung Cancer;2007, Vol. 1 Issue 2, p63 

    The article presents studies on lung cancer imaging. A study by F. Taguchi et al published in the "Journal of the National Cancer Institute" discussed the use of mass spectrometry in the classification of non-small-cell lung cancer patients treated with epidermal growth factor receptor tyrosine...

  • The utility of positron emission tomography in the treatment planning of image-guided radiotherapy for non-small cell lung cancer. Chi, Alexander; Nguyen, Nam P. // Frontiers in Oncology;Oct2014, Vol. 4, p1 

    In the thorax, the extent of tumor may be more accurately defined with the addition of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) to computed tomography (CT). This led to the increased utility of FDG-PET or PET/CT in the treatment planning of radiotherapy for non-small cell...

  • Imaging metrics predicted OS in NSCLC treated with stereotactic ablative radiotherapy.  // Hem/Onc Today;7/10/2013, Vol. 14 Issue 13, p32 

    The article reports that positron emission tomography/computed tomography imaging before treatment can help predict the survival chances of patients with non-small cell lung cancer treated with stereotactic ablative radiotherapy.

  • Inter- and intraobserver consistency in assessing eligibility for bevacizumab (BVZ) in non-small-cell lung cancer (NSCLC) patients with centrally located tumors. Barlési, F.; Balleyguier, C.; Besse, B.; Bonodeau, F.; Brenac, F.; Corneloup, O.; Dansin, E.; Ferretti, G.; Gaubert, J. Y.; Gervais, R.; Lacombe, C.; Loundou, A.; Moro-Sibilot, D.; Planchard, D.; Scherpereel, A.; Menu, Y. // Annals of Oncology;Aug2010, Vol. 21 Issue 8, p1682 

    Background: Bevacizumab (BVZ) combined with platinum-based therapy is registered for first-line treatment of nonsquamous non-small-cell lung cancer (NSCLC). Patients with centrally located tumors are stated ineligible for BVZ treatment. The goal of this study was to assess the consistency in...

  • PET--CT in lung cancer: data discrepancies. Paredes, Jose M.; Mehta, Jayesh // Thorax;Dec2011, Vol. 66 Issue 12, p1092 

    A letter to the editor is presented in response to the Danish study of positron emission tomography (PET)-computer tomography (CT) versus conventional staging (CS) in non-small cell lung cancer.

  • PET--CT in lung cancer: data discrepancies. Fischer, Barbara M.; Mortensen, Jann; Højgaard, Liselotte // Thorax;Dec2011, Vol. 66 Issue 12, p1092 

    A response by Barbara M. Fischer and colleagues to a letter to the editor about their study of positron emission tomography (PET)-computer tomography (CT) versus conventional staging (CS) in non-small cell lung cancer is presented.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics